咪唑立宾对难治性原发性肾病综合征疗效观察

Effect of mizoribine on refractory nephropathy syndrome

目的:观察咪唑立宾(MZR)治疗难治性原发性肾病综合征的疗效及安全性。方法:11例难治性原发性肾病综合征患者予MZR 150 mg,每日1次或分3次口服,疗程6个月;同时口服泼尼松0.8～1.0 mg.kg-1.d-1,并逐渐减量。治疗前及治疗后3、6个月测定患者24 h尿蛋白定量、血清白蛋白、血常规、尿常规和肝肾功能,观察记录不良反应。结果:经治疗,患者24 h尿蛋白定量下降,血清白蛋白水平上升(P<0.05),治疗前后肾功能无明显变化,未发现明显不良反应。结论:MZR治疗难治性原发性肾病综合征有效,也无明显副作用。

Objective： To observe the efficacy and safety of mizoribine（MZR） in treatment of refractory nephropathy syndrome. Methods： Eleven patients with refractory nephropathy syndrome were treated by MZR.The clinical data was observed in the 3rd month and 6th month.Results： The proteinuria of the patients decreased while serum albumin increased significantly（P〈0.05） after the patients received MZR treatment, and serious side effect was not observed. Conclusion： MZR is an effective and safe drug in the treatment of refractory nephropathy syndrome.